NovoCure Limited (NASDAQ:NVCR – Free Report) – Stock analysts at HC Wainwright issued their FY2030 earnings per share estimates for NovoCure in a report issued on Tuesday, January 13th. HC Wainwright analyst E. Bodnar expects that the medical equipment provider will post earnings of $3.28 per share for the year. HC Wainwright has a “Buy” rating and a $39.00 price objective on the stock. The consensus estimate for NovoCure’s current full-year earnings is ($1.30) per share.
NovoCure (NASDAQ:NVCR – Get Free Report) last released its quarterly earnings results on Thursday, October 30th. The medical equipment provider reported ($0.33) EPS for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.09. NovoCure had a negative return on equity of 50.29% and a negative net margin of 27.66%.The company had revenue of $167.20 million for the quarter, compared to analyst estimates of $158.81 million. During the same quarter last year, the firm posted ($0.28) earnings per share. NovoCure’s revenue was up 7.8% compared to the same quarter last year.
Get Our Latest Stock Analysis on NovoCure
NovoCure Price Performance
NASDAQ NVCR opened at $13.80 on Wednesday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.50 and a current ratio of 1.55. The stock has a market cap of $1.55 billion, a price-to-earnings ratio of -8.57 and a beta of 0.73. The business has a 50 day simple moving average of $12.71 and a 200 day simple moving average of $13.22. NovoCure has a 52-week low of $10.70 and a 52-week high of $27.47.
Hedge Funds Weigh In On NovoCure
A number of large investors have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of NovoCure by 17.1% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,307 shares of the medical equipment provider’s stock valued at $77,000 after acquiring an additional 629 shares in the last quarter. Arizona State Retirement System grew its stake in NovoCure by 3.0% in the third quarter. Arizona State Retirement System now owns 31,313 shares of the medical equipment provider’s stock valued at $405,000 after purchasing an additional 916 shares in the last quarter. Alliancebernstein L.P. increased its position in shares of NovoCure by 0.8% during the 3rd quarter. Alliancebernstein L.P. now owns 137,106 shares of the medical equipment provider’s stock worth $1,771,000 after purchasing an additional 1,076 shares during the last quarter. KLP Kapitalforvaltning AS increased its position in shares of NovoCure by 6.5% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 23,000 shares of the medical equipment provider’s stock worth $409,000 after purchasing an additional 1,400 shares during the last quarter. Finally, Rhumbline Advisers raised its stake in shares of NovoCure by 1.2% during the 2nd quarter. Rhumbline Advisers now owns 152,749 shares of the medical equipment provider’s stock worth $2,719,000 after purchasing an additional 1,797 shares in the last quarter. 84.61% of the stock is currently owned by institutional investors and hedge funds.
NovoCure News Roundup
Here are the key news stories impacting NovoCure this week:
- Positive Sentiment: Piper Sandler reaffirmed a Buy on NVCR, signaling continued confidence in the company’s therapy adoption and longer‑term growth potential. Piper Sandler Remains a Buy on NovoCure (NVCR)
- Positive Sentiment: HC Wainwright still carries a Buy rating and a $39 price target and published a long‑range FY2030 EPS model projecting strong upside, supporting a bullish longer‑term view despite nearer‑term cuts. HC Wainwright Lowers NovoCure (NASDAQ:NVCR) Price Target to $39.00
- Neutral Sentiment: Wedbush reaffirmed a Neutral rating with an $18 price target (~30% above current levels), which could cap upside until clearer near‑term fundamentals emerge. Benzinga: Wedbush neutral on NovoCure
- Neutral Sentiment: Market consensus remains a Hold/Neutral across analysts, reflecting mixed views on timing of revenue progression vs. ongoing losses. NovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of “Hold” by Analysts
- Neutral Sentiment: Management presented at the J.P. Morgan Healthcare Conference (transcript available) — useful for qualitative updates and investor Q&A but no immediate new financial guidance reported. NovoCure Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Negative Sentiment: HC Wainwright cut near‑term EPS estimates across multiple 2026 quarters and trimmed FY2026–2029 forecasts, signaling weaker near‑term profitability expectations that could pressure the stock until revenue trends accelerate. HC Wainwright Lowers NovoCure (NASDAQ:NVCR) Price Target to $39.00
- Negative Sentiment: Wells Fargo issued a Hold on NVCR, which removes a buy-side endorsement from a major desk and may limit near‑term retail/institutional buying momentum. NovoCure (NVCR) Gets a Hold from Wells Fargo
About NovoCure
NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.
Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.
See Also
- Five stocks we like better than NovoCure
- NEW LAW: Congress Approves Setup For Digital Dollar?
- Look who’s buying 2 tonnes of gold… per week!
- Virtually Unknown AI Company Solving Trillion-Dollar Problem
- Do not delete, read immediately
- How a Family Trust May Be Able To Help Preserve Your Wealth
Receive News & Ratings for NovoCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure and related companies with MarketBeat.com's FREE daily email newsletter.
